Lay Line Genomics re-launches AntiTrkA project for the treatment of chronic pain

Rome-based Lay Line Genomics SpA says that, after the termination of the exclusive license agreement with fellow Italian firm BioXell SpA, all rights to the humanized antiTrkA monoclonal antibody named BXL1H5 are now fully back in its hands.

"BioXell advanced the development of the therapeutic antibody in the preclinical stages, reaching relevant results in the characterization of the product, in in vivo tests and filing new intellectual property, so making stronger an already very solid package of patents," stated Ennio Esposito, sole administrator of LLG.

He continued: "Based on those achievements as well as from an important positive outcome of the appeal of LLG's base patent at EPO [European Patent Office], LLG will now take-over the work on BXL1H5. We are very excited about the opportunity to re-launch this project which offers enormous potential from an industrial point of view. The NGF/TrkA mechanism for the treatment of chronic and inflammatory pain has always been a high priority topic in our agenda: this is now well recognized also in the market, placing LLG in a uniquely strong position in the booming field of therapeutic antibodies for chronic pain".